You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Heterologous prime-boost

Showing 1 - 25 of 1,464
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

COVID-19 Trial in Al Ain (AZD1222, rAd26-S)

Completed
  • COVID-19
  • AZD1222
  • rAd26-S
  • Al Ain, United Arab Emirates
    Tawam Hospital
Oct 24, 2022

Covid-19, Vaccine, Immunogenicity Trial in Taoyuan (Heterologous prime-boost schedule with AZD1222 and MVC-COV1901, Homologous

Recruiting
  • Covid-19
  • +4 more
  • Heterologous prime-boost schedule with AZD1222 and MVC-COV1901
  • Homologous prime-boost schedule with two doses of AZD1222
  • Taoyuan, Taiwan
    ChangGungMH
Oct 19, 2021

Covid19 Vaccine Trial in Taipei (Homologous boost schedule, Heterologous boost schedule)

Active, not recruiting
  • Covid19 Vaccine
  • Homologous boost schedule
  • Heterologous boost schedule
  • Taipei, Taiwan
    National Taiwan University Hospital
Nov 28, 2021

COVID-19 Trial in Nanjing (Ad5-nCoV-IH, Ad5-nCoV-IM, CoronaVac)

Active, not recruiting
  • COVID-19
  • Ad5-nCoV-IH
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Diseases Control and Prevention
Aug 12, 2022

Covid19 Trial in Maputo (BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell), Ad26.COV2.S (Recombinant,

Recruiting
  • Covid19
  • BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)
  • +2 more
  • Maputo, Mozambique
    Centro de Investigação e Treino em Saúde da Polana Caniço - Inst
Mar 31, 2022

COVID-19 Trial in Bizerte, Ariana, Tunis (CoronaVac/CoronaVac, CoronaVac/BNT162b2)

Completed
  • COVID-19
  • CoronaVac/CoronaVac
  • CoronaVac/BNT162b2
  • Bizerte, Mateur, Tunisia
  • +4 more
Jan 4, 2023

Chronic Hepatitis B Trial in Hamburg (HEPLISAV B; TherVacB, TherVacB)

Not yet recruiting
  • Chronic Hepatitis B
  • HEPLISAV B; TherVacB
  • TherVacB
  • Hamburg, Germany
    CTC North
Feb 3, 2023

COVID-19 Trial in Moscow, Saint-Petersburg, St. Petersburg (AZD1222, rAd26-S)

Completed
  • COVID-19
  • AZD1222
  • rAd26-S
  • Moscow, Russian Federation
  • +3 more
Jun 2, 2022

COVID-19 Trial in Singapore (Homologous mRNA booster vaccine, Heterologous mRNA booster vaccine, Non-mRNA booster vaccine A)

Recruiting
  • COVID-19
  • Homologous mRNA booster vaccine
  • +4 more
  • Singapore, Singapore
    National Centre for Infectious Diseases (NCID)
Nov 30, 2021

COVID-19 Trial in Nanjing (recombinant Ad5 vectored COVID-19 vaccine, RBD-based protein subunit vaccine (ZF2001) against

Completed
  • COVID-19
  • recombinant Ad5 vectored COVID-19 vaccine
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Diseases Control and Prevention
Mar 28, 2022

Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma Trial in Nashville (DNA Vaccine, Human Papillomavirus

Not yet recruiting
  • Metastatic Oropharyngeal Carcinoma
  • Recurrent Oropharyngeal Carcinoma
  • DNA Vaccine
  • +6 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Mar 22, 2023

HIV-1 Trial in Worldwide (Ad26.Mos4.HIV, Clade C gp140, Placebo)

Completed
  • HIV-1
  • Ad26.Mos4.HIV
  • +2 more
  • Lilongwe, Malawi
  • +22 more
Apr 12, 2022

Dengue Virus Trial in Silver Spring (TDENV-PIV, TDENV-LAV F17)

Active, not recruiting
  • Dengue Virus
  • TDENV-PIV
  • TDENV-LAV F17
  • Silver Spring, Maryland
    WRAIR, Clinical Trials Center
Mar 25, 2021

Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain

Completed
  • SARS-CoV 2 Infection
  • Covid19
  • BBIBP-CorV
  • BNT162b2
  • Manama, Bahrain
    Royal College of Surgeons in Ireland - Bahrain
Oct 25, 2021

HIV Trial (DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine)

Withdrawn
  • HIV Infections
  • DNA-HIV-PT123 vaccine
  • +4 more
  • (no location specified)
Oct 13, 2021

SARS-CoV2 Infection Trial in Innsbruck (Vaxzevria, Comirnaty)

Recruiting
  • SARS-CoV2 Infection
  • Vaxzevria
  • Comirnaty
  • Innsbruck, Tyrol, Austria
    Medical University of Innsbruck
Sep 9, 2021

Hemorrhagic Fever, Ebola Trial in Worldwide (Ad26.ZEBOV, MVA-BN-Filo, Placebo)

Completed
Has Results
  • Hemorrhagic Fever, Ebola
  • Ad26.ZEBOV
  • +2 more
  • Silver Spring, Maryland
  • +6 more
Jan 27, 2022

COVID-19, Breakthrough Infection Trial in Taoyuan city (BNT162b2, mRNA-1273, MVC-COV1901)

Active, not recruiting
  • COVID-19
  • Breakthrough Infection
  • BNT162b2
  • +2 more
  • Taoyuan city, Taiwan
    Chang Gung Memorial Hospital
Jul 21, 2022

HIV Trial in United States (DNA Vaccine, DNA Vaccine , rAd35)

Completed
  • HIV Infections
  • DNA Vaccine
  • +5 more
  • Birmingham, Alabama
  • +9 more
Oct 13, 2021

Patients With Cancer, Vaccine Reaction, COVID-19 Trial in Beijing (Coronavirus vaccination)

Recruiting
  • Patients With Cancer
  • +2 more
  • Coronavirus vaccination
  • Beijing, China
    302 Hospital
Apr 11, 2022

Chronic Hepatitis B Trial in Hong Kong, Auckland (VRON-0200-AdC6, VRON-0200-AdC7)

Recruiting
  • Chronic Hepatitis B
  • VRON-0200-AdC6
  • VRON-0200-AdC7
  • Hong Kong, Hong Kong
  • +1 more
Oct 6, 2023

COVID-19 Vaccines Trial in Panama, Philippines, United States (UB-612, BNT162b2 vaccine, ChAdOx1-S vaccine)

Active, not recruiting
  • COVID-19 Vaccines
  • UB-612
  • +3 more
  • Brownsville, Texas
  • +6 more
Oct 11, 2022

Influenza A Virus, H5N1 Subtype Trial in United States (VN, IN, dk/BANG)

Completed
Has Results
  • Influenza A Virus, H5N1 Subtype
  • VN
  • +6 more
  • San Diego, California
  • +5 more
Jun 30, 2020

Hemorrhagic Fever, Ebola Trial in Worldwide (Ad26.ZEBOV, MVA-BN-Filo, Placebo)

Completed
Has Results
  • Hemorrhagic Fever, Ebola
  • Ad26.ZEBOV
  • +2 more
  • BoboDioulasso, Burkina Faso
  • +6 more
Feb 9, 2022

COVID-19 Trial (UB-612)

Withdrawn
  • COVID-19
  • UB-612
  • (no location specified)
Feb 13, 2022